Le marché des thérapies ARNi était évalué à 618,79 millions de dollars US en 2019 et devrait atteindre 1 209,29 millions de dollars US d'ici 2027 ; il devrait croître à un TCAC de 8,8 % de 2020 à 2027.
L'ARNi fait référence à l'ARN d'interférence qui est chargé de contrôler et de manipuler la traduction des protéines dans la cellule. Ces ARNi sont utilisés pour réduire au silence certains gènes responsables de maladies. À l'heure actuelle, la sensibilisation à l'ARNi augmente en raison de sa capacité à offrir un mécanisme spécifique à une cible, conduisant à des résultats de traitement supérieurs. L'approche est largement utilisée pour le développement de médicaments. L'augmentation des investissements dans le développement de la thérapie ARNi, associée à la prévalence croissante des maladies infectieuses et des affections chroniques, devrait stimuler la croissance du marché des thérapies ARNi au cours de la période de prévision. Cependant, le coût élevé impliqué dans le développement des thérapies ARNi est susceptible de freiner la croissance du marché. au cours des années de prévision.
Régions lucratives pour le marché des thérapies ARNi
Aperçu du marché
Investissements croissants dans les thérapies ARNi
R&D continue Les activités thérapeutiques de l'ARNi ont révélé ses avantages dans la lutte contre une gamme de troubles chroniques tels que les maladies génétiques, les troubles rénaux, les maladies neurodégénératives et l'oncologie. L'efficacité des résultats des thérapies ARNi génère des investissements dans le développement de nouveaux médicaments. Par exemple, en septembre 2018, Curamir Therapeutics, Inc. a reçu une aide financière initiale de 10 millions de dollars américains de Delos Capital pour développer des médicaments à base de miARN pour le cancer résistant à la chimiothérapie. De plus, en avril 2019, Alnylam Pharmaceuticals Inc. a annoncé son partenariat stratégique avec Regeneron Pharmaceuticals pour découvrir et commercialiser une plateforme thérapeutique ARNi pour le traitement des maladies associées aux yeux, au système nerveux central et au foie. Les entreprises ont investi environ 1 milliard de dollars américains dans la collaboration. De plus, en janvier 2020, Dicerna Pharmaceuticals, Inc. et Novo Nordisk ont collaboré pour développer des thérapies ARNi pour le traitement des maladies du foie et des troubles cardiométaboliques. Dicerna Pharmaceuticals, Inc. a reçu un paiement initial d'environ 175 millions de dollars US de Novo Nordisk pour le lancement du projet. De plus, selon les termes du partenariat, Dicerna Pharmaceuticals, Inc. recevra près de 25 millions de dollars américains par an de Novo Nordisk pendant les trois premières années pour le développement du produit. De tels investissements aident les entreprises biotechnologiques et pharmaceutiques non seulement à lancer de nouveaux produits, mais aussi à augmenter le nombre de produits approuvés. Par exemple, en août 2018, Alnylam Pharmaceuticals, Inc. a reçu une approbation de la Food and Drug Administration (FDA) des États-Unis pour sa thérapie par perfusion Onpattro utilisée pour le traitement de la maladie des nerfs périphériques (polyneuropathie). Les acteurs du marché gagnent des investissements dans la R&D de nouveaux médicaments, thérapies et technologies. Ces investissements croissants dans les thérapies ARNi stimulent la croissance du marché.
Informations basées sur le type de molécule
Sur la base du type de molécule, le marché des thérapies ARNi est segmenté en petits ARN interférents (siRNA ) et microARN (miARN). Le segment des petits ARN interférents (siARN) détenait une plus grande part du marché en 2019. La croissance de ce segment est attribuée à la préférence croissante pour les petits ARN interférents pour le développement de médicaments et au nombre croissant de partenariats de recherche. En outre, le segment des microARN (miARN) devrait enregistrer un TCAC plus élevé sur le marché mondial des thérapies ARNi au cours de la période de prévision.
Marché mondial des thérapies ARNi, par type de molécule - 2019& 2027
Application-Based Insights
Sur la base des applications, le marché des thérapies ARNi est segmenté en oncologie, cardiovasculaire, troubles respiratoires, maladies rénales, troubles génétiques, troubles neurodégénératifs, maladies infectieuses et autres . En 2019, le segment de l'oncologie représentait la plus grande part du marché mondial des thérapies ARNi en raison de la préférence croissante pour les thérapies ARNi pour le traitement du cancer. De plus, le nombre croissant de collaborations de recherche dans le domaine de l'oncologie devrait également stimuler la croissance du segment d'ici 2027. Cependant, le segment des troubles cardiovasculaires devrait enregistrer le TCAC le plus élevé du marché au cours de la période de prévision.
Informations basées sur la voie d'administration
Sur la base de la voie d'administration, le marché des thérapies ARNi est segmenté en administration pulmonaire, injections intraveineuses, injections intradermiques, injections intrapéritonéales et autres. En 2019, le segment de l'administration pulmonaire représentait la plus grande part du marché mondial des thérapies ARNi. Cependant, on estime que le segment des injections intraveineuses enregistre le TCAC le plus élevé du marché au cours de la période de prévision. Un nombre important de lancements de produits et une adoption accrue de l'injection intraveineuse sont susceptibles d'avoir un impact positif sur la croissance du segment.
Insights basés sur l'utilisateur final
Sur la base de l'utilisateur final, le marché des thérapies ARNi est davantage segmenté en laboratoires de recherche et universitaires, hôpitaux et laboratoires de diagnostic. Le segment des laboratoires de recherche et universitaires détenait la plus grande part du marché en 2019 et devrait enregistrer le TCAC le plus élevé au cours de la période de prévision.
Perspectives stratégiques
Les lancements de produits et les stratégies d'expansion sont généralement adoptés par aux entreprises d'étendre leur présence dans le monde et de répondre à la demande croissante. Cette stratégie est le plus souvent adoptée par les acteurs du marché afin d'élargir leur portefeuille de produits.
Les acteurs du marché opérant sur le marché de la thérapeutique ARNi ont adopté la stratégie d'innovation produit pour répondre à l'évolution de la demande des clients à travers le monde, ce qui permet également aux joueurs de conserver leur marque à l'échelle mondiale.
Les impacts mondiaux du COVID-19 se font sentir sur plusieurs marchés. Dans le cas de l'industrie pharmaceutique, les opérations de la chaîne d'approvisionnement sont considérablement entravées en raison de la pandémie. Cependant, les acteurs du marché de la thérapeutique ARNi se concentrent sur le développement de vaccins à l'aide de la technologie de silençage génique, ce qui pourrait avoir un impact positif sur la croissance du marché au cours de la période de prévision.
Par type de molécule
- Petits ARN interférents (siARN)
- MicroARN (miARN)
Par application
- Oncologie< /li>
- Cardiovasculaire
- Troubles respiratoires
- Maladies rénales
- Troubles génétiques
- Troubles neurodégénératifs
- Maladies infectieuses
- Autres
Par voie d'administration
- Accouchement pulmonaire
- Injections intraveineuses
- Injections intradermiques
- Injections intrapéritonéales
- Autres
Par utilisateur final
- Laboratoires de recherche et universitaires
- Hôpitaux
- Laboratoires de diagnostic
Marché des thérapies ARNi Par zone géographique
- Amérique du Nord
- États-Unis
- Canada
- Mexique
- Europe
- France
- Allemagne< /li>
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Asie-Pacifique (APAC)
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
- Moyen-Orient et amp ; Afrique (MEA)
- Afrique du Sud
- Arabie saoudite
- EAU
- Reste de la MEA
- Amérique du Sud et centrale (SAM)
- Brésil
- Argentine
- Reste de SAM
Profils des sociétés
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
- États-Unis
- Canada
- Mexique
- France
- Allemagne< /li>
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'APAC
- Afrique du Sud
- Arabie saoudite
- EAU
- Reste de la MEA
- Brésil
- Argentine
- Reste de SAM
Profils des sociétés
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
RNAi refers to the interference RNA which is responsible to control and manipulate protein translation in the cell. These RNAi are used to silence particular genes which are responsible for diseases. Currently, the awareness about RNAi is increasing extensively due to its ability to offer target specific mechanism, leading to superior treatment outcomes.
The factors that are driving growth of the market are growing investments in RNAitherapies and rising prevalence of chronic conditions and infectious diseases.Moreover, strategic activities by the manufacturersare offering lucrative opportunities for the growth of the market.
The RNAi therapeutics market majorly consists of the players such as Alnylam Pharmaceuticals, Inc., Sanofi, Olix Pharmaceuticals, Inc., Glaxosmithkline Plc., Benitec Biopharma, Arbutus Biopharma Corporation, Silence Therapeutics, Rexahn Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Inc., and Quark amongst others.
The List of Companies - RNAi Therapeutics Market
- Alnylam Pharmaceuticals, Inc.
- Sanofi
- Olix Pharmaceuticals, Inc.
- Glaxosmithkline Plc.
- Benitec Biopharma
- Arbutus Biopharma Corporation
- Silence Therapeutics
- Rexahn Pharmaceuticals, Inc.
- Arrowhead Pharmaceuticals, Inc
- Quark
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Aug 2020
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Aug 2020
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Aug 2020
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Aug 2020
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Aug 2020
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Aug 2020
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Aug 2020
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)